Whan In Pharm Co.,Ltd. (KRX:016580)
9,840.00
-160.00 (-1.60%)
Aug 21, 2026, 3:30 PM KST
Whan In Pharm Revenue
Whan In Pharm had revenue of 71.42B KRW in the quarter ending June 30, 2026, with 11.36% growth. This brings the company's revenue in the last twelve months to 273.47B, up 5.71% year-over-year. In the year 2025, Whan In Pharm had annual revenue of 255.21B, down -1.69%.
Revenue (ttm)
273.47B
Revenue Growth
+5.71%
P/S Ratio
0.67
Revenue / Employee
431.35M
Employees
634
Market Cap
181.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 255.21B | -4.38B | -1.69% |
| Dec 31, 2024 | 259.60B | 29.20B | 12.68% |
| Dec 31, 2023 | 230.39B | 31.46B | 15.81% |
| Dec 31, 2022 | 198.93B | 21.16B | 11.90% |
| Dec 31, 2021 | 177.78B | 6.07B | 3.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 952.66B |
| Daewon Pharmaceutical | 614.64B |
| Samjin Pharmaceuticals | 274.03B |
| JW Lifescience | 252.72B |
| Daihan Pharmaceutical | 211.44B |
| Boditech Med | 165.84B |
| REYON Pharmaceutical | 145.22B |
| Hyundai Pharmaceutical | 108.14B |